Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 14

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 14
---
 The Pro Forma                                                                                  
 As Adjusted data gives additional effect to: (i) the sale of  1,000,000 Ordinary               
 Shares in this offering at an initial public offering price of $11.00 per Ordinary Share,      
 which is the midpoint of the price range set forth on the cover page of this prospectus,       
 after deducting underwriting discounts and commissions and estimated offering expenses payable 
 by us; (ii) repayment of the Bridge Loan in the total amount of $350,000 plus accrued interest 
 and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the loan       
 under the 2024 Loan Agreements in the total amount of $150,000 plus accrued interest and       
 an aggregate risk premium in the amount of $50,000; (iv) the repayment of loan under the       
 December 2024 Loan Agreement in the total amount of $117,000 plus value added tax, or VAT,     
 plus accrued interest and an aggregate risk premium of approximately $35,100  plus VAT;        
 (v) the repayment of the loan under the 2025 Loan Agreements in the total amount of $200,000   
 plus accrued interest and an aggregate risk premium in the amount of $100,000; and (vi) total  
 payment of $430,000 to CSL Behring GmbH, or CSL, in connection with the CSL Settlement (as     
 defined below).                                                                                |

The as adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. Each $0.25 increase (decrease) in the assumed initial public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents, total assets and shareholders’ equity (deficiency) by $0.23 million, assuming that the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000 in the number of Ordinary Shares offered by us at the assumed initial public offering price would increase (decrease) each of cash, cash equivalents and short-term deposits, total assets and shareholders’ equity (deficiency)